BACLOFEN

Product NDC
52817-321
11-digit product format
528170321
Labeler code
52817
Product ID
52817-321_1645f54e-2eed-bd9b-e063-6294a90a848b
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
BACLOFEN
Dosage form
TABLET
Route
ORAL
Labeler
TruPharma LLC
Application
ANDA209102
Marketing category
ANDA
Marketing start
2018-04-01
Substance
BACLOFEN
Active strength
20 mg/1
Pharmacologic classes
GABA A Agonists [MoA], GABA B Agonists [MoA], gamma-Aminobutyric Acid-ergic Agonist [EPC]
NDC exclude flag
No
Listing certified through
2026-12-31
Current FDA listing
Yes

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A209102-001BACLOFENBACLOFEN5MGTABLET / ORALAB2017-11-28
A209102-002BACLOFENBACLOFEN10MGTABLET / ORALAB2017-11-28
A209102-003BACLOFENBACLOFEN20MGTABLET / ORALAB2017-11-28
A209102-004BACLOFENBACLOFEN15MGTABLET / ORALAB2024-02-05

Therapeutic equivalence codes#

Application-product, TE code table
Application-productTE code
A209102-001AB
A209102-002AB
A209102-003AB
A209102-004AB

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
BACLOFENBACLOFENTruPharma LLC68aa591e-ea98-4438-9a4a-4f7e9ea2b2852024-04-17Warnings, Adverse reactionsExact identifier

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings

WARNINGS a. Neonatal Withdrawal Symptoms: Withdrawal symptoms have been reported starting hours to days after delivery in neonates whose mothers were treated with oral baclofen throughout pregnancy. The symptoms of withdrawal in these infants have included increased muscle tone, tremor, jitteriness, and seizure. If the potential benefit justifies the potential risk to the fetus and oral baclofen is continued during pregnancy, gradually reduce the dose and discontinue baclofen before delivery. If slow withdrawal is not feasible, advise the parents or caregivers of the potential for neonatal withdrawal. b. Abrupt Drug Withdrawal: Hallucinations and seizures have occurred on abrupt withdrawal of baclofen. Therefore, except for serious adverse reactions, the dose should be reduced slowly when the drug is discontinued. c. Impaired Renal Function: Because baclofen is primarily excreted unchanged through the kidneys, it should be given with caution, and it may be necessary to reduce the dosage. d. Stroke: Baclofen has not significantly benefited patients with stroke. These patients have also shown poor tolerability to the drug. e. Pregnancy: Baclofen has been shown to increase the incidence of omphaloceles (ventral hernias) in fetuses of rats given approximately 13 times the maximum dose recommended for human use, at a dose which caused significant reductions in food intake and weight gain in dams. This abnormality was not seen in mice or rabbits. There was also an increased incidence of incomplete sternebral ossification in fetuses of rats given approximately 13 times the maximum recommended human dose, and an increased incidence of unossified phalangeal nuclei of forelimbs and hindlimbs in fetuses of rabbits given approximately 7 times the maximum recommended human dose. In mice, no teratogenic effects were observed, although reductions in mean fetal weight with consequent delays in skeletal ossification were present when dams were given 17 and 34 times the human daily dose. There are no studies in pregnant women. Baclofen should be used during pregnancy only if the benefit clearly justifies the potential risk to the fetus.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

ADVERSE REACTIONS The most common is transient drowsiness (10 to 63%). In one controlled study of 175 patients, transient drowsiness was observed in 63% of those receiving baclofen compared to 36% of those in the placebo group. Other common adverse reactions are dizziness (5 to 15%), weakness (5 to 15%) and fatigue (2 to 4%). Others reported: Neuropsychiatric: Confusion (1 to 11%), headache (4 to 8%), insomnia (2 to 7%); and, rarely, euphoria, excitement, depression, hallucinations, paresthesia, muscle pain, tinnitus, slurred speech, coordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizure. Cardiovascular: Hypotension (0 to 9%). Rare instances of dyspnea, palpitation, chest pain, syncope. Gastrointestinal: Nausea (4 to 12%), constipation (2 to 6%); and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhea, and positive test for occult blood in stool. Genitourinary: Urinary frequency (2 to 6%); and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, hematuria. Other: Instances of rash, pruritus, ankle edema, excessive perspiration, weight gain, nasal congestion. Some of the CNS and genitourinary symptoms may be related to the underlying disease rather than to drug therapy. The following laboratory tests have been found to be abnormal in a few patients receiving baclofen: increased SGOT, elevated alkaline phosphatase, and elevation of blood sugar.

Additional Listing Data#

Finished product
Yes
Brand name base
BACLOFEN
Listing expiration
2026-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
BACLOFEN20 mg/1

Harmonized Identifiers#

Field, Values table
FieldValues
UniiH789N3FKE8
Rxcui197391, 197392, 430902, 2679605

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
1e25d01b-2e92-4765-bec7-8a0fd7bdc346Product name220251208
1b1393e5-f2d8-42f5-a070-e3416d619667Product name120250804
88583480-702d-4dfe-a31c-9c00abd818f8Product name720250729
1cf3c538-592e-4b4b-869e-51d4bf3ca83dProduct name220240703
6e532d1f-e0b5-46eb-a2be-d70bd338df9dProduct name120220613
ef6bc0bf-8134-f06b-70d9-4980df6f808eProduct name520210615
eeec0918-7a2f-44bf-83d6-1216e507adbfProduct name320191217
a5300adb-f538-4abb-a49e-f8f0b8d9ac75Product name120190611

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
52817-321-00BACLOFEN1000 in 1 BOTTLETABLET10004
52817-321-10BACLOFEN100 in 1 BOTTLETABLET1004
52817-321-50BACLOFEN500 in 1 BOTTLETABLET5004

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
52817-321-00EA - Each52817-321cbdc2453-b045-4feb-ae75-28b52c0d2fa812018-05-09
52817-321-10EA - Each52817-321bd5a7c5f-f74b-4443-816c-82d151d08c1712018-05-09

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
52817-321BACLOFEN TABLET [TRUPHARMA LLC]4Current NDC, Legacy NDC, 3 package rows20240418_68aa591e-ea98-4438-9a4a-4f7e9ea2b285.zip

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
197392baclofen 20 MG Oral TabletPSN5cba5255-e5ad-48fd-8385-60e9ea6b64077
197392baclofen 20 MG Oral TabletPSNc85a9d82-1d61-aeec-e053-2995a90a03a47
197392baclofen 20 MG Oral TabletSCDc85a9d82-1d61-aeec-e053-2995a90a03a47
197392baclofen 20 MG Oral TabletSCD5cba5255-e5ad-48fd-8385-60e9ea6b64077
197392baclofen 20 MG Oral TabletPSNadc072b9-e48b-470d-9eb1-fd7b52c1f1225
197392baclofen 20 MG Oral TabletSCDadc072b9-e48b-470d-9eb1-fd7b52c1f1225
197391baclofen 10 MG Oral TabletPSN68aa591e-ea98-4438-9a4a-4f7e9ea2b2854
2679605baclofen 15 MG Oral TabletPSN68aa591e-ea98-4438-9a4a-4f7e9ea2b2854
197392baclofen 20 MG Oral TabletPSN020632f4-5e8a-f4a0-e063-6294a90a63014
197392baclofen 20 MG Oral TabletPSN68aa591e-ea98-4438-9a4a-4f7e9ea2b2854
430902baclofen 5 MG Oral TabletPSN68aa591e-ea98-4438-9a4a-4f7e9ea2b2854
197391baclofen 10 MG Oral TabletSCD68aa591e-ea98-4438-9a4a-4f7e9ea2b2854
2679605baclofen 15 MG Oral TabletSCD68aa591e-ea98-4438-9a4a-4f7e9ea2b2854
197392baclofen 20 MG Oral TabletSCD68aa591e-ea98-4438-9a4a-4f7e9ea2b2854
197392baclofen 20 MG Oral TabletSCD020632f4-5e8a-f4a0-e063-6294a90a63014
430902baclofen 5 MG Oral TabletSCD68aa591e-ea98-4438-9a4a-4f7e9ea2b2854
2679605baclofen 15 MG Oral TabletSY68aa591e-ea98-4438-9a4a-4f7e9ea2b2854
197391baclofen 10 MG Oral TabletPSN35bccefe-8d2e-85b5-e063-6394a90a58ca2
2679605baclofen 15 MG Oral TabletPSN35bccefe-8d2e-85b5-e063-6394a90a58ca2
197392baclofen 20 MG Oral TabletPSN4e2cd27d-91c7-4f15-96cc-3971769dbeaa2
197392baclofen 20 MG Oral TabletPSN35bccefe-8d2e-85b5-e063-6394a90a58ca2
430902baclofen 5 MG Oral TabletPSN35bccefe-8d2e-85b5-e063-6394a90a58ca2
197391baclofen 10 MG Oral TabletSCD35bccefe-8d2e-85b5-e063-6394a90a58ca2
2679605baclofen 15 MG Oral TabletSCD35bccefe-8d2e-85b5-e063-6394a90a58ca2
197392baclofen 20 MG Oral TabletSCD35bccefe-8d2e-85b5-e063-6394a90a58ca2
197392baclofen 20 MG Oral TabletSCD4e2cd27d-91c7-4f15-96cc-3971769dbeaa2
430902baclofen 5 MG Oral TabletSCD35bccefe-8d2e-85b5-e063-6394a90a58ca2
2679605baclofen 15 MG Oral TabletSY35bccefe-8d2e-85b5-e063-6394a90a58ca2

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startMarketing endSampleExclude flagStatus
52817-321-00528170321001000 TABLET in 1 BOTTLE (52817-321-00) 1000 tablet2018-04-010000-00-00NoNoCurrent
52817-321-1052817032110100 TABLET in 1 BOTTLE (52817-321-10) 100 tablet2018-04-010000-00-00NoNoCurrent
52817-321-5052817032150500 TABLET in 1 BOTTLE (52817-321-50) 500 tablet2018-04-010000-00-00NoNoCurrent